Optoacoustic Imaging of Glucagon-like Peptide-1 Receptor with a Near-Infrared Exendin-4 Analog.
J Nucl Med · 2021
Last updated 2026-05-28Researchers developed a new imaging tool called E4-Cy7, which uses near-infrared light to target and visualize cells with GLP-1 receptors, such as those in pancreatic islets. In lab tests, E4-Cy7 showed strong binding ability (with a dissociation constant of 4.6 ± 0.8 nM) and successfully allowed imaging of insulin-producing tumors in live animals for the first time using optoacoustic technology.
AI summary of the abstract below.
| Journal | J Nucl Med, 2021 |
|---|---|
| Citations | 6 |
| Relative citation ratio | 0.42 |
| NIH percentile | 25 |
| Molecules | — |
Abstract
Limitations in current imaging tools have long challenged the imaging of small pancreatic islets in animal models. Here, we report the first development and in vivo validation testing of a broad-spectrum and high-absorbance near-infrared optoacoustic contrast agent, E4-Cy7. Our near-infrared tracer is based on the amino acid sequence of exendin-4 and targets the glucagon-like peptide-1 receptor (GLP-1R). Cell assays confirmed that E4-Cy7 has a high-binding affinity (dissociation constant, Kd, 4.6 ± 0.8 nM). Using the multispectral optoacoustic tomography, we imaged E4-Cy7 and optoacoustically visualized β-cell insulinoma xenografts in vivo for the first time. In the future, similar optoacoustic tracers that are specific for β-cells and combines optoacoustic and fluorescence imaging modalities could prove to be important tools for monitoring the pancreas for the progression of diabetes.
Verbatim abstract via PubMed 33097631 ↗